Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
At the ESCMID Global 2026, Bruker Corporation unveiled a wide-ranging set of portfolio enhancements spanning microbial identification, outbreak surveillance, and reflex next-generation sequencing (NGS) workflows. These updates reflect the company’s strategic focus on delivering integrated, high-performance microbiology solutions that enable laboratories to respond more effectively to the growing complexity of infectious disease diagnostics and public health threats.
Advancing MALDI Biotyper Workflows and Identification Capabilities
A central pillar of Bruker’s announcement is the continued evolution of its MALDI-TOF mass spectrometry ecosystem, anchored by the MALDI Biotyper platform. To improve efficiency and standardization in routine workflows, Bruker introduced the MBT Easy T Kit, a proprietary consumables solution designed to simplify the sample transfer process onto MALDI target plates.
The MBT Easy T Kit provides ready-to-use reagents and applicators, allowing laboratories to process up to 2,000 samples with a single kit. By enabling room-temperature storage and reducing the need for manual reagent preparation, the kit minimizes operational complexity and chemical waste. This approach is particularly valuable in high-throughput clinical laboratories where consistency, reproducibility, and time efficiency are critical. Standardization of sample preparation steps not only improves workflow reliability but also enhances the quality of downstream identification results.
In parallel with workflow improvements, Bruker has significantly expanded its MALDI Biotyper reference libraries. The updated libraries now include coverage for more than 5,300 microbial species, spanning bacteria, yeasts, filamentous fungi, and mycobacteria. This expansion includes the addition of over 600 new species, strengthening diagnostic confidence across a broader range of pathogens.
A notable area of enhancement is the MyT workflow for filamentous fungi, which now benefits from approximately 30% increased species coverage. This is particularly relevant for clinical microbiology laboratories dealing with invasive fungal infections, where accurate and timely identification can directly impact treatment decisions. Bruker has also indicated that corresponding updates to IVDR-registered libraries are currently underway, ensuring compliance with European regulatory standards.
Cloud-Based Identification and Expert Knowledge Integration
To extend the reach of specialized microbial identification resources, Bruker is introducing early access to a cloud-based MALDI identification solution within the MBT Compass HT environment. This research-use-only (RUO) offering allows selected expert laboratories and key opinion leaders to access curated libraries maintained by domain specialists.
Initial cloud-based libraries include collections focused on yeast species, anaerobic bacteria developed in collaboration with academic institutions, and mosquito identification datasets supporting malaria vector research. By leveraging cloud infrastructure, laboratories gain visibility into the provenance and curation of reference data, enhancing transparency and trust in identification results.
This cloud-enabled approach also lays the groundwork for future capabilities such as exclusive library access, remote system monitoring, and streamlined software updates. As microbiology continues to evolve toward more connected and data-driven workflows, such innovations position Bruker at the forefront of digital transformation in laboratory diagnostics.
Automation of Sample Preparation Workflows
Automation remains a key focus area for Bruker, as laboratories seek to reduce manual labor and improve throughput. The company is advancing two important systems currently undergoing IVDR-compliant clinical validation: MBT PrepMatic and MBT SepsiMatic.
MBT PrepMatic is designed to automate colony selection from Petri dishes and prepare MALDI target plates with minimal human intervention. This semi- to fully automated process reduces variability and accelerates sample preparation, particularly in high-volume laboratories.
Meanwhile, MBT SepsiMatic focuses on streamlining workflows for positive blood cultures. The system is engineered to process samples directly from blood culture bottles to MALDI target plates, potentially delivering purified samples containing viable microorganisms suitable for further downstream analyses. This capability could significantly shorten the time required to identify bloodstream infections, enabling faster clinical decision-making.
Expanding Clinical and Research Applications
Bruker is also advancing the clinical utility of its MALDI-based technologies through ongoing research and validation studies. In the United States, clinical trials are underway to support regulatory submissions for the identification of mycobacteria and filamentous fungi, with plans for submission to the U.S. Food and Drug Administration in 2026.
Another major area of development is rapid phenotypic antimicrobial susceptibility testing (AST) using MALDI-TOF mass spectrometry. Bruker is conducting clinical validation studies aimed at enabling same-day AST results from positive blood cultures and agar colonies, particularly for Enterobacteriaceae. This approach incorporates machine-learning-based growth analysis and aligns conceptually with established methodologies such as broth microdilution, guided by organizations like CLSI and EUCAST.
In addition, Bruker is exploring the application of artificial intelligence to predict antibiotic resistance directly from MALDI spectra. At ESCMID Global 2026, the company presented preliminary research data demonstrating promising results for Staphylococcus aureus, achieving an area under the receiver operating characteristic curve (AUROC) greater than 0.8 based on analysis of more than 2,600 spectra. While still in the exploratory stage, these findings highlight the potential of AI-driven diagnostics to complement traditional susceptibility testing methods.
Enhancing Hospital Hygiene and Outbreak Management
Beyond individual patient diagnostics, Bruker is strengthening its capabilities in epidemiology and infection control. The IR Biotyper platform has been expanded with new applications, including IR Tracker for monitoring hospital-acquired infections (HAIs).
The latest updates introduce new classifiers targeting clinically significant pathogens such as Salmonella Typhi, Shiga toxin-producing Escherichia coli (STEC), and Shigella species. These organisms are associated with high infectivity, specific treatment considerations, and mandatory public health reporting. Rapid classification and differentiation of such pathogens are essential for outbreak detection and containment, particularly in hospital settings where infection control is critical.
By integrating IR-based typing with MALDI identification and sequencing workflows, Bruker is enabling a more comprehensive approach to microbial surveillance and epidemiology.
Integrating Reflex NGS and Culture-Independent Diagnostics
In the area of genomic analysis, Bruker introduced an updated version of its MBioSEQ Ridom Typer platform. The new release supports both short- and long-read whole genome sequencing (WGS) data, enabling advanced analysis for research and expert laboratory applications.
Key enhancements include integration of TB-Profiler for antimicrobial resistance determination and GAMBIT for bacterial species identification. These tools facilitate reflex workflows in which MALDI or IR Biotyper results trigger follow-up genomic analysis, providing deeper insights into pathogen characteristics and resistance mechanisms.
Further strengthening its portfolio, Bruker highlighted the integration of Molzym following its acquisition in late 2025. Molzym brings specialized expertise in culture-independent pathogen detection, including its patented MolYsis technology. This method selectively removes host DNA from clinical samples, enabling more sensitive detection of microbial DNA, particularly in low-biomass or blood samples. Such capabilities are critical for advancing sequencing-based diagnostics and improving detection rates in challenging clinical scenarios.
Expert Perspectives and Strategic Vision
Industry experts have underscored the practical impact of these innovations. Kirsten Schönfeld of Institut Dr. Nowak GmbH noted that standardized, ready-to-use reagents are essential for maintaining efficient MALDI workflows. Solutions like the MBT Easy T Kit help simplify laboratory operations, reduce logistical challenges, and ensure consistent performance in clinical settings.
Dr. Wolfgang Pusch, President of Bruker’s Microbiology & Infection Diagnostics Division, emphasized that these developments are driven by continuous feedback from laboratory professionals. He highlighted the company’s broad innovation strategy, which includes expanding reference libraries, advancing automation, and exploring AI-based approaches to antibiotic resistance prediction.
At the same time, Bruker is investing in clinical studies to validate rapid AST solutions, enhancing the analytical capabilities of the IR Biotyper, and refining its NGS-based platforms for applications such as tuberculosis resistance profiling. This multi-pronged approach reflects a commitment to addressing both current and emerging challenges in infectious disease diagnostics.
A Comprehensive Vision for the Future of Microbiology
Taken together, the announcements at ESCMID Global 2026 illustrate Bruker’s vision for a fully integrated microbiology ecosystem. By combining MALDI-TOF identification, infrared typing, automated sample preparation, and genomic sequencing, the company is creating a cohesive framework that supports laboratories across the entire diagnostic workflow.
These innovations are particularly timely as healthcare systems worldwide face increasing pressures from antimicrobial resistance, emerging pathogens, and the need for rapid, data-driven decision-making. High-throughput, automated, and interconnected diagnostic platforms are becoming essential tools in this landscape.
In conclusion, Bruker’s latest portfolio enhancements reinforce its position as a leader in microbiology and infection diagnostics. Through continued investment in technology, collaboration, and clinical validation, the company is equipping laboratories with the tools needed to improve efficiency, enhance diagnostic accuracy, and ultimately support better patient outcomes in the fight against infectious diseases.
About Bruker Corporation – Leader of the Post-Genomic Era
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.
Source Link:https://www.businesswire.com/
